BRAIN.Q Overview
BRAIN.Q is redefining the future of neurological recovery, with a mission to transform lives through innovative, noninvasive therapies. The company utilizes advanced AI-powered technology to develop network-targeting electromagnetic precision therapy, designed to enhance and accelerate brain recovery following ischemic stroke—the leading cause of disability worldwide. Delivered through a cloud-based platform, the therapy is seamlessly adaptable for both hospital and home settings. Celebrated as a pioneer in neurological innovation, BRAIN.Q has earned CE Mark approval, the FDA’s Breakthrough Device Designation, and the esteemed recognition of the European Innovation Council. Building on these advancements, BRAIN.Q is actively progressing its pivotal EMAGINE II study in the U.S., aiming to secure FDA clearance for its Q Therapeutic System and expand its transformative impact on patient recovery. Guided by a world-class leadership team and a bold vision for the future of neurological recovery, BRAIN.Q is driven by its mission to restore brain health and dignity to stroke survivors, empowering them to regain independence.
Cumulative Funding Raised Over Time ($)
$39.0MAug 2021
$42.5MMay 2017
$49.8MMay 2018
Latest News
Research Examines Electromagnetic Device to Improve Stroke Recovery
BRAIN.Q's helmet's tailored, low-intensity, low frequency electromagnetic stimulation aims to enhance and accelerate the brain's recovery after stroke.
BRAIN.Q is Advancing Stroke Care Through Innovative Technologies
BRAIN.Q Recognized as a Tech Pioneer by WEF 2024 for Its Innovative Brain Health Platform to Treat Stroke Disability
growth-positive
First Patient Enrolled in BrainQ's Pivotal Trial, EMAGINE™, for Frequency-Tuned Electromagnetic Field Therapy to Reduce Disability Following Ischemic Stroke
BrainQ has enrolled the first patient in its EMAGINE Stroke Recovery Trial, which aims to evaluate the effectiveness of its frequency-tuned electromagnetic field treatment in facilitating recovery in individuals with moderately-severe ischemic stroke. The trial provides a remote and decentralized care model and will enroll 150 randomized subjects. The primary outcome measure is the modified Rankin Scale (mRS), and the investigational therapy is intended to be used adjunctively with physical or occupational therapy. BrainQ aims to extend the window of opportunity for reducing disability from the acute phase to the sub-acute phase of stroke recovery. The trial has the potential to make a significant impact on the stroke survivor population suffering from long-term disability.
CustomersPartners
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $52.4M |
| Last funding | $39M |
| Stage | B |
| Rounds | 4 |
| Investors | 11 |
Team Members
6
Employees: 11-50
Web & Social Links
| Website | brainqtech.com |
Locations
Givat Ram, Jerusalem, Israel
560 Sylvan Ave 3rd floor, Englewood Cliffs, NJ 07632, USA
Photos & Videos
3 item(s)
BRAIN.Q Business
Business models
B2B2C, B2B
Product stage
Clinical Trial
Employees
11-50
Sector
Health Tech & Life SciencesDigital HealthcareDigital TherapeuticsTarget Customer
Healthcare & Life SciencesHealthcarePatientsProvidersCore Technology
Artificial IntelligenceMachine LearningTags (17)
non-invasivestrokedegenerative-diseasesmedical-devicesneurologyrehabilitationartificial-intelligencemachine-learningdigital-healthcareclinicshospitalsmedical-technologiesneurosciencedigital-therapeuticspatientswearablemhealthGeographic Markets
GlobalNorth AmericaIndiaIsraelEuropeBRAIN.Q Financials
$52.4M
Total funding
Undisclosed
Capital raised
$39M
Last funding
B
Funding stage
4
Total rounds
11
Investors
Cumulative Funding Raised Over Time ($)
$39.0MAug 2021
$42.5MMay 2017
$49.8MMay 2018
Private Equity Funding
B Round
Aug 2021
$39M
Hanaco Ventures (Lead), OurCrowd (Lead)
,
IT-Farm, Dexcel Pharma, RunYoung Technology Transfer Center, Sailing Capital, Millhouse Capital, Qure Ventures, Peregrine Ventures
A Round
May 2018
$7.3M
Qure Ventures, Natura Investments, IT-Farm, OurCrowd
Seed
May 2017
$3.5M
OurCrowd, Undisclosed Investor(s)
Non-Equity Funding
GrantEvent
Jun 2018
$2.6M
Horizon 2020 accelerator (Lead)
BRAIN.Q Lifecycle
Cumulative Funding Raised Over Time
$39.0MAug 2021
$42.5MMay 2017
$49.8MMay 2018
All Events
B Round
Aug 2021
$39M
Hanaco Ventures (Lead), OurCrowd (Lead)
,
IT-Farm, Dexcel Pharma, RunYoung Technology Transfer Center, Sailing Capital, Millhouse Capital, Qure Ventures, Peregrine Ventures
A Round
May 2018
$7.3M
Qure Ventures, Natura Investments, IT-Farm, OurCrowd
Seed
May 2017
$3.5M
OurCrowd, Undisclosed Investor(s)
GrantEvent
Jun 2018
$2.6M
Horizon 2020 accelerator (Lead)
BRAIN.Q News
16 articlesResearch Examines Electromagnetic Device to Improve Stroke Recovery
BRAIN.Q's helmet's tailored, low-intensity, low frequency electromagnetic stimulation aims to enhance and accelerate the brain's recovery after stroke.
BRAIN.Q is Advancing Stroke Care Through Innovative Technologies
BRAIN.Q Recognized as a Tech Pioneer by WEF 2024 for Its Innovative Brain Health Platform to Treat Stroke Disability
growth-positive
First Patient Enrolled in BrainQ's Pivotal Trial, EMAGINE™, for Frequency-Tuned Electromagnetic Field Therapy to Reduce Disability Following Ischemic Stroke
BrainQ has enrolled the first patient in its EMAGINE Stroke Recovery Trial, which aims to evaluate the effectiveness of its frequency-tuned electromagnetic field treatment in facilitating recovery in individuals with moderately-severe ischemic stroke. The trial provides a remote and decentralized care model and will enroll 150 randomized subjects. The primary outcome measure is the modified Rankin Scale (mRS), and the investigational therapy is intended to be used adjunctively with physical or occupational therapy. BrainQ aims to extend the window of opportunity for reducing disability from the acute phase to the sub-acute phase of stroke recovery. The trial has the potential to make a significant impact on the stroke survivor population suffering from long-term disability.
CustomersPartners
growth-positive
BrainQ raises $40M to transform stroke patient rehabilitation with its home therapy device
BrainQ, a medical technology company, has raised $40 million to bring its device for stroke rehabilitation to market. The device stimulates the damaged part of the brain and promotes self-repair. BrainQs technology has received a Breakthrough Device certification from the FDA and has shown promising results in studies. The device uses low-intensity magnetic field therapy to resonate in the brain and facilitate its endogenous recovery mechanisms. By targeting stroke-affected areas, the device promotes neuroplasticity and expedites recovery. BrainQ plans to conduct a larger-scale study with 12 sites, partnering with top hospitals and research organizations in the field of stroke rehabilitation. The recent funding round was led by Hanaco Ventures, with participation from Dexcel Pharma and Peregrine Ventures.
Investment
growth-positive
https://www.jpost.com/health-science/israeli-startup-develops-artificial-brainwaves-to-treat-strokes-661881
Israeli startup BrainQ has developed an innovative therapeutic platform for treating stroke victims using artificial brainwaves delivered through a wearable device. Clinical trials showed that 77% of subjects using the treatment recovered faster from strokes compared to those not using it. The treatment stimulates the nervous system to regrow and heal itself through electromagnetic radiation. The results of the study will be presented at the International Stroke Conference in late March. The therapy has the potential to extend the time period for corrective therapy delivery and be applicable to a larger patient population. BrainQ aims to bring their therapy to market and become the leading home-based neuro-therapeutics solution.
CustomersInvestment
growth-positive
https://www.jpost.com/health-science/israeli-stroke-therapy-granted-fda-breakthrough-device-status-658988
Israeli start-up BrainQs artificial intelligence stroke therapy has been given Breakthrough Device designation by the US Food and Drug Administration (FDA). The designation will allow BrainQ to work with the FDA to expedite the development and clearance process of its device. BrainQs therapy is designed to reduce disability caused by stroke through a non-invasive, AI-powered, electromagnetic field therapy. The therapy is delivered through a wearable device that is connected to the cloud, allowing for portable treatment that can be used in the patients home.
PartnersExpand
growth-positive
BrainQ gets FDA Breakthrough status for its device for reducing disability following stroke
BrainQ, an Israeli start-up, has received Breakthrough Device designation from the FDA for its AI-powered technology that aims to reduce disability following stroke. The designation allows BrainQ to work closely with the FDA to expedite development plans and gain premarket clearance. It also grants access to the Medicare Coverage of Innovative Technology pathway, enabling concurrent Medicare coverage with FDA market authorization. BrainQs therapy is based on AI-powered electromagnetic field therapy delivered via a cloud-connected wearable device. The company aims to extend the window of opportunity for stroke treatment beyond the acute phase. The FDA designation is seen as an important milestone in BrainQs mission to reduce disability for stroke patients and provide treatment at home. The company has also added a new member to its Board of Directors, Eilon D. Kirson, MD, PhD.
CustomersPartners
growth-positive
Electromagnetic stimulation may improve arm and hand function after spinal cord injury
BrainQ Technologies has granted a research grant to Ghaith Androwis, PhD, and Steven Kirshblum, MD, to study a potential treatment for arm and hand dysfunction in individuals with chronic spinal cord injury. The study aims to test the safety and effectiveness of a brain-computer interface-based electromagnetic field treatment. The researchers will use the BQ System to deliver noninvasive low-frequency electromagnetic field stimulation. The study will be conducted at multiple centers, including Kessler Foundation, The Miami Project to Cure Paralysis, and Sheba Medical Center. The goal is to improve motor function and control in individuals with spinal cord injury and enhance their overall quality of life.
Partners
Start-Up Spotlight: BrainQ Forsees New Era For Neurodisorder Treatment
growth-positive
https://www.jpost.com/Jpost-Tech/Business-and-Innovation/Hillels-Tech-Corner-Using-your-brain-580061?fbclid=IwAR1fCrQfRmU2rlNbnBwaslxr3PjewILnWEwhY8U55DXZm7x7Izo2p5BCnFo
The article discusses BrainQ, a technology company based in Jerusalem. BrainQ is focused on developing an AI-based medical device that facilitates human motor recovery following neurological trauma. The device is a brain-computer interface (BCI) that uses AI to translate brain data into treatment for patients with spinal cord injury, stroke, and traumatic brain injury. The company has raised $8.8 million in funding and has been selected by Google as one of four companies expected to transform healthcare with AI. BrainQ is currently in clinical trials and aims to expand into the treatment of other conditions. The company plans to lease or sell the device to hospitals and clinics and eventually create a home device. BrainQ has patents granted in major markets and is collaborating with leading institutes in the US and Europe.
InvestmentExpand
growth-positive
BrainQ raises $5.3M to treat neurological disorders with the help of AI
BrainQ, an Israel-based startup that aims to help stroke victims and those with spinal cord injuries treat their injuries with the help of a personalized electromagnetic treatment protocol, has raised a $5.3 million funding round. The companys investors include Qure Ventures, OurCrowd.com, Norma Investments, IT-Farm, and angel investors. BrainQ uses the patients brainwaves to generate a tailored treatment protocol and owns one of the largest Brain Computer Interface-based EEG databases for motor tasks. The company is focused on AI-based precision medicine for neuro-recovery. The team includes former members of Israels elite intelligence units and academics with a background in AI and neuroscience.
Investment
growth-positive
A company wants to put a chip in your brain to cure disease
Israel-based neurotech startup BrainQ is developing a non-invasive approach to integrating the human brain with technology. The company is using EEG machines to record brain activity, a technique that has been used by other groups working with paralyzed patients. BrainQ hopes to use this technology to improve the lives of stroke and spinal cord injury patients. The company faces several challenges, including completing human clinical trials, gaining FDA approval, and competing with other companies developing similar technology. BrainQ hopes to have the technology available in the U.S. market by 2020.
Expand
growth-positive
BrainQ aims to cure stroke and spinal cord injuries through mind-reader tech
Israel-based neurotech startup BrainQ plans to use non-surgically embedded EEG machines to gather data and improve outcomes for stroke and spinal cord patients. The company is conducting two human clinical trials in Israel and aims to enter the US market by 2020. BrainQ is also considering expanding into Alzheimers research and childrens syndromes. While facing competition in the neurotech space, BrainQ believes it is ahead of companies like Kernel and Neuralink. The company has raised $3.5 million from Israeli investors and angels and has presented clinical findings at the World Congress of Neuro Rehabilitation.
CustomersInvestment
growth-positive
Israeli startup BrainQ tapped for Google AI program
Israeli startup BrainQ Technologies has been chosen to participate in Google’s prestigious artificial intelligence development program in San Francisco. BrainQ is working on a product designed to enable paralyzed patients to walk. Google’s program, Launchpad Studio, offers participants access to Google’s resources and mentorship. BrainQ launched in 2016 and has 10 employees, and is currently developing its product and carrying out clinical trials in Israel.
Expand
BRAIN.Q Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 35 |
| Team members | 6 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 9 classification IDs that could be used for matching.
BRAIN.Q Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 100/100 |
| Missing | markets |
| BI Verification | Sharon Shapira |
| Registrar ID | 514654904 |
| Crunchbase | brainq |
| Phone | +972549421773 |
| Creator | Raz Zohar |
| Creator email | raz@platterz.ca |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2022-08-24T00:00:00.000Z |
| Created | 2014-09-28T00:00:00.000Z |
| Claimed | Yes |